Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC)
| Autor: | I. Malik, M. MacDonald, S. Jerian, Lynn Navale, Neal J. Meropol, G. Croghan, Amita Patnaik, J. R. Hecht, Alan P. Venook, Jordan Berlin |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Oncology
Cancer Research Chemotherapy medicine.medical_specialty biology business.industry Colorectal cancer medicine.medical_treatment Phases of clinical research medicine.disease Oxaliplatin Irinotecan stomatognathic diseases Internal medicine Cohort medicine biology.protein Panitumumab Epidermal growth factor receptor business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 23:3520-3520 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2005.23.16_suppl.3520 |
| Popis: | 3520 Background: Panitumumab (formerly ABX-EGF) is a fully human monoclonal antibody that binds with high affinity to the epidermal growth factor receptor (EGFr). This ongoing phase 2 study is evaluating the safety and efficacy of panitumumab monotherapy in patients (pts) with mCRC who have failed standard chemotherapy. Here we present mature unaudited data from the ongoing study. Methods: Pts with mCRC who failed therapy with a fluoropyrimidine (± leucovorin) and either irinotecan or oxaliplatin, or both, were eligible for this study. Cohort A included pts with EGFr staining of 2+ or 3+ in ≥ 10% tumor cells; cohort B included pts with EGFr staining of the sum of 1+, 2+ and 3+ in ≥ 10% of tumor cells, but with the sum of 2+ and 3+ in < 10% of tumor cells. Panitumumab was given IV at 2.5 mg/kg once weekly in 8-wk cycles. Pts continued receiving treatment until disease progression or unacceptable toxicity occurred. Endpoints included tumor response (RECIST), time to disease progression, survival, and safety... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|